Cullinan Therapeutics (CGEM) said Wednesday that the European Medicines Agency has approved its application to conduct a phase 1 clinical trial for CLN-978 to potentially treat rheumatoid arthritis.
The biopharmaceutical company said the open-label trial will be initiated in Q2 to assess the safety, pharmacokinetics, pharmacodynamics, and effects of CLN-978 in patients with active, difficult-to-treat rheumatoid arthritis.
Cullinan said the study will be held at FAU Erlangen-Nuremberg in Germany and Universita Cattolica del Sacro Cuore in Rome, the company added.
Price: 7.70, Change: -0.10, Percent Change: -1.28
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。